This study is looking at how well two different treatments, Emicizumab and Factor VIII (FVIII), prevent bleeding in young people with moderate to severe Hemophilia A (a genetic bleeding disorder where your blood doesn't clot properly) who play sports. Researchers want to see which treatment leads to fewer bleeding episodes over two years. You might be able to join if you are between 6 and 19 years old, have moderate to severe Hemophilia A without inhibitors (antibodies that can make FVIII treatment less effective), and are already on one of these standard treatments. This is an observational study, meaning researchers will watch and collect information about your current treatment and how it affects bleeding.

Study design

This is an observational study planning to include 72 participants. It compares two groups: those on standard Emicizumab prophylaxis and those on standard FVIII prophylaxis.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for two years to measure the number of bleeding events.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.